A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Daniel P HurkmansEdwin A BasakTanja van DijkDarlene MerciecaMarco W J SchreursAnnemarie J M WijkhuijsSander BinsEsther Oomen-de HoopReno DebetsMarkus JoergerArlette OdinkAstrid A M van der VeldtCor H van der LeestJoachim G J V AertsRon H J MathijssenStijn L W KoolenPublished in: Journal for immunotherapy of cancer (2019)
Based on the first real-world population-PK model of nivolumab, covariate analysis revealed a significant effect of gender, BSA, and albumin on nivolumab clearance. A clearance-response relationship was observed in NSCLC, with a non-significant trend in RCC, but not in melanoma. Individual pharmacology of nivolumab in NSCLC appears important and should be prospectively studied.